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ETV4 transcription factor and MMP13
metalloprotease are interplaying actors of
breast tumorigenesis
Mandy Dumortier1, Franck Ladam2, Isabelle Damour1, Sophie Vacher3, Ivan Bièche3, Nathalie Marchand1,
Yvan de Launoit1, David Tulasne1 and Anne Chotteau-Lelièvre1,4*
Abstract
Background: The ETS transcription factor ETV4 is involved in the main steps of organogenesis and is also a
significant mediator of tumorigenesis and metastasis, such as in breast cancer. Indeed, ETV4 is overexpressed in
breast tumors and is associated with distant metastasis and poor prognosis. However, the cellular and molecular
events regulated by this factor are still misunderstood. In mammary epithelial cells, ETV4 controls the expression of
many genes, MMP13 among them. The aim of this study was to understand the function of MMP13 during ETV4-
driven tumorigenesis.
Methods: Different constructs of the MMP13 gene promoter were used to study the direct regulation of MMP13 by
ETV4. Moreover, cell proliferation, migration, invasion, anchorage-independent growth, and in vivo tumorigenicity
were assayed using models of mammary epithelial and cancer cells in which the expression of MMP13 and/or ETV4
is modulated. Importantly, the expression of MMP13 and ETV4 messenger RNA was characterized in 456 breast
cancer samples.
Results: Our results revealed that ETV4 promotes proliferation, migration, invasion, and anchorage-independent
growth of the MMT mouse mammary tumorigenic cell line. By investigating molecular events downstream of ETV4,
we found that MMP13, an extracellular metalloprotease, was an ETV4 target gene. By overexpressing or repressing
MMP13, we showed that this metalloprotease contributes to proliferation, migration, and anchorage-independent
clonogenicity. Furthermore, we demonstrated that MMP13 inhibition disturbs proliferation, migration, and invasion
induced by ETV4 and participates to ETV4-induced tumor formation in immunodeficient mice. Finally, ETV4 and
MMP13 co-overexpression is associated with poor prognosis in breast cancer.
Conclusion: MMP13 potentiates the effects of the ETV4 oncogene during breast cancer genesis and progression.
Keywords: ETV4, Transcription factor, MMP13, Tumorigenesis, Breast cancer
Background
ETV4, together with ETV1 and ETV5, constitutes the
PEA3 group among the 12 subgroups of the ETS tran-
scription factor family, defined by their conserved DNA
binding domain (ETS binding domain) [1, 2]. They con-
trol the development of various organs and are involved
in the progression of many cancers, including breast
cancer [1, 3–8]. ETV4 directly influences the outcome of
mammary tumorigenesis induced by the ERBB2, steroid
receptor coactivator 1, and Wnt1 oncogenes [9–11].
However, the cellular and molecular mechanisms
regulated by the ETV4 factor during mammary cancer
progression are still poorly understood.
In most cases, carcinogenesis is associated with an
overexpression of ETV4 promoting proliferation, migra-
tion, and/or invasion involved in the tumorigenic and/or
metastatic process. As a consequence, deregulation of
ETV4 target genes has a key role in these processes. Few
ETV4 target genes involved in the regulation of these
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biological responses have been described so far, particu-
larly in the mammary cells and tissues. In these latter
cases, ETV4 has been shown to regulate the expression
of several matrix metalloproteases (MMPs), such as
MMP2 or MMP9; transcription factors involved in
epithelial-to-mesenchymal transition (EMT), such as
Twist1 or Snail; or other cancer-related factors, such as
Bax, cyclin D3, or cyclin D2. Therefore, they play an active
role during the acquisition of invasive properties by mam-
mary cancer cells [8, 10, 12–15]. A transcriptome-wide
identification of ETV4-responsive genes in mammary cells
has shown that many more genes are potentially regulated
by ETV4, although it is still unclear if they are direct tar-
gets and what roles they could play in the context of
ETV4-driven tumorigenesis [16]. Therefore, the precise
characterization of ETV4 target genes in the context of
mammary tumorigenesis will allow a better understanding
of the molecular mechanisms involved in this pathology.
MMP13 is one of those genes and was identified as
being downregulated following ETV4 knock-down in
mammary epithelial cells [16]. MMP13 (collagenase 3) be-
longs to the collagenase subfamily of MMPs and degrades
all fibrillary collagens, particularly the type II collagen
[17]. MMP13 has a role in different kind of cancer [18]
and is overexpressed in a variety of malignant tumors [19].
It was first identified from overexpressing breast carcin-
omas [20]. Although the role of MMP13 in mammary
tumorigenesis has been reported [18, 21–27], its regula-
tion in the oncogenic process is still misunderstood.
Indeed, MMP13 is expressed in the endothelium sur-
rounding breast tumors, suggesting a role in the modula-
tion of extracellular matrix degradation and cell-matrix
interactions involved in metastasis [20, 28]. Consistently,
functional evidence demonstrates that MMP13 increases
the invasive capacities of the malignant cells in breast can-
cer [29–31]. Yet, the precise role of the MMP13 protein
and how the MMP13 gene is transcriptionally regulated
during mammary tumorigenesis remain unclear.
On the basis of the results of this study, we first report
that MMP13 is an ETV4 target gene in various mam-
mary cellular models, and we identify an ETS binding
site necessary for the direct regulation of the MMP13
gene promoter by ETV4. Second, by establishing ETV4-
and MMP13-overexpressing and MMP13-repressing
MMT cells to assess modification of the phenotypic
cellular properties, we show that ETV4 significantly
promotes cell proliferation, migration, invasion, and
anchorage-independent growth. Moreover, we provide
evidence that MMP13, to a lesser extent, presents the
same contribution. Next, we assess the consequences of
MMP13 knock-down in ETV4-controlled events. Inter-
estingly, MMP13 inhibition disturbs the positive effect
of ETV4 on MMT proliferation, migration, and invasion,
and we demonstrate that MMP13 acts as a relay of
ETV4 in its functional role in the mammary epithelial
tumorigenic cells in vitro as well as in tumor graft assays
in vivo. Finally, we investigate the ETV4-MMP13 link in
breast cancer samples and describe that the association
of both ETV4 and MMP13 overexpression is associated
with poor patient outcome. Ultimately, these data shed
light on a new ETV4 relay, the extracellular metallopro-
tease MMP13, which could potentially be targeted in the
context of ETV4-controlled mammary tumorigenesis.
Methods
Cell culture and reagents
The TAC murine mammary epithelial cell line [32, 33]
was cultured on collagen-coated plates in Gibco
high-glucose DMEM (Thermo Fisher Scientific, Waltham,
MA, USA) supplemented with 10% FCS, penicillin
(110 IU/ml), and streptomycin (110 μg/ml). A wild-type
mouse mammary tumor (MMT) cell line (ATCC®
CCL-51™; American Type Culture Collection, Manassas, VA,
USA) was cultured in DMEM supplemented with 10% (vol/
vol) FBS, gentamicin (100 IU/ml), and nonessential amino
acids (Gibco; Thermo Fisher Scientific). The MCF10A cell
line (ATCC® CRL-10317™; American Type Culture Collec-
tion) was propagated in DMEM/F-12 medium (Gibco;
Thermo Fisher Scientific) supplemented with 5% horse
serum, 20 ng/ml epidermal growth factor, 100 ng/ml cholera
toxin, 500 ng/ml hydrocortisone, and 0.01 mg/ml insulin.
Plasmids
pTracer-ETV4 and pLPCX-ETV4-V5 plasmids were de-
scribed previously [8, 12, 32]. pMX-MMP13 was gener-
ated by PCR amplification of the mouse MMP13
complementary DNA (cDNA) and cloned into the
pMX-Puro retroviral vector. pRS-shMMP13 retroviral
plasmid was kindly provided by S. Meierjohann [34].
pGL3 constructs containing different parts of the
MMP13 promoter were kindly provided by J. M. David-
son [35]. Mutations to proximal ETS and activator pro-
tein (AP)-1 binding site in MMP13 promoter were made
using the QuikChange® II XL Site-Directed Mutagenesis
Kit (Agilent Technologies, Santa Clara, CA, USA). The
proximal ETS site was changed from GGAA to CCAA,
and the proximal AP-1 site was changed from
TGACT to GCACT. The sequence of all promoter
constructs was verified by DNA sequencing.
Retroviral infections and stable selection
HEK293GP packaging cells (Clontech) (3 × 106) were
transfected with pLPCX, pMX, or pRS retroviral con-
structs, and 1.2 × 106 MMTcells or 1 × 106 MCF-10A cells
per 100-mm dish were incubated with supernatant as pre-
viously described [16]. The selection procedure was
started the next day using puromycin (Life Technologies,
Carlsbad, CA, USA).
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Stable cell lines
TAC cells overexpressing ETV4 after retroviral infection
(ETV4) and control mock-infected TAC cells (ctrl) were
previously described [8]. MMT cells infected with pLPCX
retroviral vector (Ctrl) were used as a control for MMT
cells overexpressing ETV4 after retroviral infection with
the pLPCX-ETV4 vector (ETV4). MMTcells infected with
pMX retroviral vector (Ctrl) were used as a control for
MMT cells overexpressing MMP13 after retroviral infec-
tion with the pMX-MMP13 vector (MMP13).
MMT cells infected with pRS retroviral vector (shCtrl)
were used as a control for MMT cells overexpressing
shMMP13 after retroviral infection with the pRS-shMMP13
vector (shMMP13). MMT-ETV4 cells (overexpressing
ETV4) infected with pRS retroviral vector (ETV4 + shCtrl)
were used as a control for MMT-ETV4 cells overexpressing
shMMP13 after retroviral infection with the pRS-shMMP13
vector (ETV4 + shMMP13).
RNA extraction, reverse transcription, and real-time qPCR
Total RNA was extracted using the RNeasy Mini Kit accord-
ing to the manufacturer’s instructions (Qiagen, Hilden,
Germany). Total RNA (1 μg) was reverse-transcribed using
the high-capacity cDNA reverse transcription kit (Life Tech-
nologies). Specific gene expression was determined by
real-time PCR using the Fast SYBR® Green Master Mix (Life
Technologies) and the Mx3005P qPCR system (Agilent
Technologies). The results were analyzed with the compara-
tive cycle threshold method normalized to cyclophilin A and
compared with a comparator sample. The nucleotide se-
quences of the primers used were as follows: MMP13-F
(5′-TCCCTGCCCCTTCCCTATGG-3′) and MMP13-R
(5′-CTCGGAGCCTGTCAACTGTGG-3′) for the MMP13
gene (PCR product of 173 bp), ETV4-F (5′-CCGCTCGCT
GCGATACTATT-3′) and ETV4-R (5′-CGGTCAAAC
TCAGCCTTCAGA-3′) for the ETV4 gene (PCR product of
162 bp), and PPIA-F (5′-GGGAACCGTTTGTGTTTGG
T-3′) and PPIA-R (5′-TGTGCCAGGGTGGTGACTTT-3′)
for PPIA gene.
Luciferase reporter assays
TAC cells (3 × 104) were seeded in 12-well plates and
transfected with ExGen 500 (Euromedex, Strasbourg,
France) and 250 ng of DNA (200 ng of expression
vector, 25 ng of firefly luciferase reporter vector,
25 ng of the Renilla luciferase pRL-TK; Promega,
Madison, WI, USA), according to a protocol previ-
ously described [12].
Chromatin immunoprecipitation
TAC pLNCX, pLNCX-ETV4 and MMT pLPCX, pLPCX
ETV4 were fixed, lysed, and used for chromatin immuno-
precipitation (ChIP) with an anti-ETV4 immunoglobulin G
(IgG) (sc-113x; Santa Cruz Biotechnology, Dallas, TX, USA)
or a nonrelevant antibody normal rabbit IgG (sc-2027), as
described in Additional file 1. Detection of specific DNA
regions was performed by PCR using the MMP13 gene
promoter region and CCND2 gene promoter region. The
nucleotide sequences of the primers used were as follows:
MMP13 forward: 5′-TCCATTTCCCTCAGATTCTGCCA
C-3′ and MMP13 reverse: 5′- TCTCTCCTTCCCAGGGC
AAGCAT-3′ for theMMP13 gene (PCR product of 164 bp)
and CCND2 forward: 5′-GAGAGGGAGGGAAAGATTG
AAAGGA-3′ and CCND2 reverse: 5′- AGGTGGGCG
AGCGGAGCCTCAAG-3′ for the CCND2 gene (PCR
product of 212 bp).
RNA interference
MMP13 and oligonucleotides used for RNA interfer-
ence were purchased from Dharmacon (SMARTpool
ON-TARGETplus MMP13 J-047459, Dharmacon, Lafayette,
CO, USA) and consisted of a mix of four siRNAs:
J-047459-12-GGCCCAUACAGUUUGAAUA/J-047459
11-AGACUAUGGACAAAGAUUA/J-047459-10-UCA
AAUGGUCCCAAACGAA/J-047459-9-CUGCGACUC
UUGCGGGAAU. Control oligonucleotide consisted
of ON-TARGETplus nontargeting siRNA#1 (D-00181
0-01-UGGUUUACAUGUCGACUAA control siRNA).
MMT cells (3.5 × 105) were seeded in six-well plates
for reverse transfection with 75 pmol of each siRNA
and 5 μl of Lipofectamine® 2000 reagent (Thermo
Fisher Scientific) as recommended by the manufac-
turer. Cells were incubated for another 24 hours
under standard conditions before being assayed.
Western blotting
Cells were lysed in buffer made of 150 mM NaCl,
50 mM Tris-HCl, pH 7.5, 1% Nonidet P-40 (vol/vol),
1 mM sodium orthovanadate, 1 mM phenylmethylsulfo-
nyl fluoride, 10 g/ml leupeptin, and 10 g/ml aprotinin.
After scraping, cellular debris was removed by centrifu-
gation at 10,000 × g for 5 minutes. Protein concentra-
tions were determined by using a Bradford assay. For
the supernatant, a subconfluent culture was grown for
24 hours in serum-free medium, then the supernatant
was centrifuged at 3000 × g for 3 minutes. Whole-cell
extracts (50 μg) or 1:20 of supernatants were separated
in precast gels (Mini-PROTEAN® TGX Stain-Free™;
Bio-Rad Laboratories, Hercules, CA, USA) gel and
transferred onto nitrocellulose membranes (Trans-Blot
Turbo Transfer System; Bio-Rad Laboratories). After
blocking with Tris-buffered saline, 0.1% Tween, and 3%
bovine serum albumin (BSA), the membrane was probed
with the primary and secondary antibodies. The enzym-
atic activity was detected using an Amersham enhanced
chemiluminescence kit (GE Healthcare Life Sciences,
Marblehead, MA, USA). Equal transfer of proteins from
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the gel was controlled by using the stain-free system of
the gel and the membrane as well as by using an
anti-GAPDH antibody. We used anti-ETV4 1:500
(GTX114393; GeneTex, Irvine, CA, USA), anti-MMP13
1:500 (18165-1-AP; Proteintech, Rosemont, IL, USA),
anti-GAPDH 1:1000 (6C5-sc-32233; Santa Cruz Biotech-
nology), and secondary antimouse or antirabbit anti-
bodies coupled to horseradish peroxidase (HRP) (GE
Healthcare Life Sciences).
Zymography
Gelatin zymography was used to determine the activity
of MMP13. The supernatant from subconfluent
serum-free culture medium was collected, and the cells
were removed by centrifugation. Then, 40 μl of sample
were loaded onto a 10% precast polyacrylamide gel with
0.1% of gelatin (Bio-Rad Laboratories). After electro-
phoresis, the gels were renatured by soaking for 30 mi-
nutes at room temperature in 2.5% Triton X-100. The
gels were then incubated in a developing buffer (50 mM
Tris, 200 mM NaCl, 5 mM CaCl2, 0.02% Brij-35 [Milli-
poreSigma], pH 7.5) overnight at 37 °C. The gels were
stained with Coomassie Brilliant Blue R-250 and
destained in demineralized water. The transparent bands
of gelatinolytic activity were visualized as clear bands
against the blue-stained gelatin background.
Cell proliferation assays
Stable MMT cells (1.5 × 104; pLPCX/pLPCX-ETV4-pMX/
pMX-MMP13-pRS/pRS-shMMP13 and MMT-ETV4-pR
S/MMT-ETV4-pRS-shMMP13) were seeded in six-well
plates. The cells were trypsinized and counted after
10, 35, 55, 80, and 100 hours using an Invitrogen
Tali™ Image-based Cytometer (Thermo Fisher Scientific).
Each time point was counted three times.
Anchorage-independent growth
Stable MMT cells (3 × 105; pLPCX/pLPCX-ETV4-pMX/
pMX-MMP13-pRS/pRS-shMMP13 and MMT-ETV4-pRS
/MMT-ETV4-pRS-shMMP13) were seeded in 500 μl of
medium mixed with 1 ml of 0.35% agar in growth medium
(DMEM [Thermo Fisher Scientific] with 10% FBS). The
cell suspension was cast onto 12-well plates with 500 μl of
0.65% agar in growth medium, which was used as an
underlay. Growth medium was added onto the agar layer
and changed weekly. Colonies were photographed after
10 days using a light microscope (Axio Vert A.1; Carl
Zeiss Microscopy, Jena, Germany).
Cell migration assays
Boyden chamber cell migration was assayed using a
cell culture chamber insert system (BD Biosciences,
San Jose, CA, USA) with an 8-μm polyethylene tereph-
thalate (PET) membrane. Stable MMT cells (4 × 104;
pLPCX/pLPCX-ETV4-pMX/pMX-MMP13-pRS/pRS-s
hMMP13 and MMT-ETV4-pRS/MMT-ETV4-pRS-sh
MMP13) were seeded in the upper chamber in DMEM
with 10% FBS. The same medium was added in the
lower chamber. After 18 hours, cells that did not cross
the membrane were scraped off the upper side of the
membrane with a cotton swab. Cells that had migrated
to the lower side were fixed with methanol at − 20 °C
and stained with Hoechst 33258 (MilliporeSigma). The
membrane was excised from its support and mounted
on a glass side with Dako Glycergel mounting
medium (Agilent Technologies). Cells were photo-
graphed using a light microscope (Axio Vert A.1) and
counted using ImageJ software (National Institutes of
Health, Bethesda, MD, USA).
Cell invasion assays
Boyden chamber cell invasion was assayed using a cell cul-
ture chamber insert system (Corning® BioCoat™ Growth
Factor Reduced Matrigel® Invasion Chamber; Corning Life
Sciences, Corning, NY, USA) with an 8-μm PET
membrane coated with Matrigel®. Stable MMT cells
(8 × 104; pLPCX/pLPCX-ETV4-pMX/pMX-MMP13-pR
S/pRS-shMMP13 and MMT-ETV4-pRS/MMT-ETV4-p
RS-shMMP13) were seeded in the upper chamber in
DMEM with 0% FBS and 0.1% BSA. DMEM with 5%
FBS was added in the lower chamber. After 36 hours,
cells that did not cross the membrane were scraped
off the upper side of the membrane with a cotton
swab. Cells that had migrated to the lower side were
fixed with methanol at − 20 °C and stained with
Hoechst 33258. The membrane was excised from its
support and mounted on a glass side with Dako Gly-
cergel mounting medium. Cells were photographed
using a light microscope (Axio Vert A.1) and counted
using ImageJ software.
Tumor grafts
MMT pLPCX-ETV4-pRS and MMT pLPCX-ETV4-pR
S-shMMP13 cells were trypsinized, then suspended in
PBS (5 × 106 cells/ml). Cells (5 × 105) were injected
subcutaneously into the inguinal flank of 6–7-week-old
female severe combined immunodeficiency (SCID)-defi-
cient mice. A total of six mice per condition were used
in three independent experiments. Tumor size was
assessed by measuring the length and width of tumors
every 3–4 days. Tumor volume was estimated using the
formula: (length × width2)/2. The experiments were
stopped when the largest tumors reached the critical size
of about 10% of the mouse’s weight in accordance with
the ethical approval form, thus meaning between 2 and
3 weeks postinjection. At the time the mice were killed,
the tumors were removed, fixed in 4% paraformalde-
hyde, and embedded in paraffin. Results are expressed as
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the mean tumor volume for each experimental group.
All animal procedures were conducted with the approval
of and in compliance with the guidelines of the Nord
Pas de Calais Regional for Ethical Animal Care and Use
Committee (CEEA-003243.01).
IHC
IHC of paraffin-embedded mouse tumor tissue sections was
performed using anti-ETV4 (1:100, GTX100812; GeneTex),
anti-MMP13 (1:100, 18165-1-AP; Proteintech), anti-Ki67
(1:200, ab15580; Abcam, Cambridge, UK), and anti-cleaved
caspase 3 (1:100, Asp175, catalogue no. 9661; Cell Signaling
Technology, Danvers, MA, USA). Sections were incubated
with secondary HRP-conjugated antibody. Counterstaining
was performed using Mayer’s hematoxylin (Merck,
Darmstadt, Germany). Imaging was carried out using
ZEN Blue imaging software (Carl Zeiss Microscopy).
Patients and samples for MMP13 and ETV4 expression
Samples of 456 primary unilateral invasive breast tumors
excised from women managed at Curie Institute-René
Huguenin Hospital (St. Cloud, France) from 1978 to
2008 were analyzed. Immediately after biopsy or surgery,
the tumor samples were stored in liquid nitrogen until
messenger RNA (mRNA) extraction. Tumor samples
were considered suitable for our study if the proportion
of tumor cells exceeded 70%.
All patients (mean age 61.7 years, range 31–91 years)
met the following criteria: primary unilateral nonmeta-
static breast carcinoma for which complete clinical, histo-
logical, and biological data were available; no radiotherapy
or chemotherapy before surgery; and full follow-up at
Curie Institute-René Huguenin Hospital. Treatment con-
sisted of modified radical mastectomy in 278 cases
(63.6%) and breast-conserving surgery plus locoregional
radiotherapy in 159 cases (36.4%) (information available
for only 437 cases). The patients underwent a physical
examination and routine chest radiography every 3 months
for 2 years, then annually. Mammograms were done an-
nually. Adjuvant therapy was administered to 369 patients,
consisting of chemotherapy alone in 91 cases, hormone
therapy alone in 176 cases, and both treatments in 102
cases. The histological type and the number of positive ax-
illary nodes were established at the time of surgery. The
malignancy of infiltrating carcinomas was scored accord-
ing to the Scarff-Bloom-Richardson (SBR) histoprognostic
grading system. Hormone receptor (HR) [estrogen recep-
tor (ERα), progesterone receptor (PR)] and human epider-
mal growth factor receptor 2 (ERBB2) status were
determined at the protein level by using biochemical
methods (dextran-coated charcoal method, enzyme im-
munoassay, or IHC) and confirmed by qPCR assays as de-
scribed in Additional file 1.
The population was divided into four groups according
to HR (ERα and PR) and ERBB2 status, as follows: two lu-
minal subtypes [HR+ (ERα + or PR+)/ERBB2+ (n = 54)]
and [HR+ (ERα + or PR+)/ERBB2− (n = 289)]; an ERBB2+
subtype [HR− (ERα− and PR−)/ERBB2+ (n = 45)] and a
triple-negative subtype [HR− (ERα− and PR−)/ERBB2−
(n = 68)]. The median follow-up was 8.9 years (range
130 days to 33.2 years). One hundred eighty-one pa-
tients had a metastasis. Clinicopathological characteris-
tics of patients in relation to metastasis-free survival
(MFS) are provided in Additional file 2: Table S1. Ten
specimens of adjacent normal breast tissue from pa-
tients with breast cancer or normal breast tissue from
women undergoing cosmetic breast surgery were used
as sources of normal mRNA.
Statistical analysis
For in vitro and in vivo analyses, all values are expressed
the means of triplicate samples ± SE. Data were analyzed
using unpaired t tests.
For human statistical analysis, relationships be-
tween mRNA expression of genes and clinical pa-
rameters were identified using nonparametric tests,
the χ2 nonparametric test (relationship between two
qualitative parameters), and the Kruskal-Wallis H
test (relationship between one quantitative parameter
and two or more qualitative parameters). Differences
were considered significant at confidence levels
greater than 95% (P < 0.05). MFS was determined as
the interval between initial diagnosis and detection
of the first metastasis.
To visualize the efficacy of MMP13 and ETV4 mRNA
levels for discriminating between two populations (pa-
tients who developed/did not develop metastases) in the
absence of an arbitrary cutoff value, data were summa-
rized in an ROC curve. The AUC was calculated as a
single measure to discriminate efficacy. The population
was divided into four patient subgroups according to
MMP13 ROC curve value in the series of 456 breast
cancer samples and then according to ETV4 ROC curve
value in the high and low MMP13 mRNA expression
level subpopulations. Finally, the very small subgroup
(n = 16) of high MMP13/low ETV4 mRNA expression
level was merged with the subgroup (n = 66) of low
MMP13/low ETV4 mRNA expression level to obtain
a unique group of 82 patients with low ETV4 mRNA ex-
pression level. Survival distributions were estimated by the
Kaplan-Meier method, and the significance of differences
between survival rates was ascertained with the log-rank
test. The Cox proportional hazards regression model was
used to assess prognostic significance in multivariate ana-
lysis [36]. We also analyzed an independent dataset of
breast tumors for which microarray data were publicly
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available (Netherlands Cancer Institute [NKI], n = 295;
http://ccb.nki.nl/data/).
Results
MMP13 is an ETV4 target gene in mammary epithelial
cells
We previously described ETV4-regulated genes in mam-
mary tumorigenic MMT cells following ETV4 inhibition
[16]. Among them, MMPs such as MMPs 1, 2, 3, 9, and
14 were shown to be slightly regulated [16]. However,
our attention was focused on MMP13, which was identi-
fied as a potentially interesting ETV4 target gene through
large-scale transcriptomic analysis that we performed on
these MMT cells [16], thereafter completed with tran-
scriptomic analysis performed with ETV4-overexpressing
and ETV4-repressing TAC cells (unpublished data). In
these latter analyses, we found that ETV4 positively mod-
ulatesMMP13 gene expression (18.12-fold, P = 0.0014 fol-
lowing ETV4 overexpression; 0.16-fold, P = 0.02 following
ETV4 inhibition). In order to characterize the regulation
of MMP13 expression by ETV4, we used the mammary
epithelial TAC cell line overexpressing ETV4 [8] as well as
the mammary cancerous MMT cell line and the breast
epithelial MCF10A cell line, engineered to overexpress a
V5-tagged ETV4 protein after a retroviral infection
(MMT-ETV4 and MCF10A-ETV4) (Fig. 1a and c and
Additional file 3: Figure S1a and c). Overexpression of
ETV4 upregulates MMP13 mRNA and protein expression
in the mouse TAC, MMT (Fig. 1b and d) and human
MCF10A cells (Additional file 3: Figure S1b and d).
Moreover, the secretion of the active form of MMP13 is
increased in the supernatant of ETV4-overexpressing
cells, as shown by Western blotting (Fig. 1e) and
zymography (Fig. 1f ).
We next completed these data by analyzing the
ETV4-regulated MMP13 promoter. TAC cells were
transfected with various MMP13 gene promoter frag-
ments cloned into a luciferase reporter vector and ETV4
expression vector or control vector. Our results indicate
that the MMP13 promoter (− 1800) is active in TAC
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cells. Moreover, ETV4 transactivates the MMP13 gene
promoter region spanning 1800 bp downstream from the
translation start codon (MMP13; − 1800) (Fig. 2a and b).
To delineate the responsive elements driving the promoter
activity, we tested various deletion constructs (Fig. 2a) and
identified a region of 91 bp (MMP13–91), which displays
an optimal promoter activity as well as induction by
ETV4 (Fig. 2b). This region contains a putative ETS bind-
ing site (EBS) and a putative AP-1 binding site. These two
sites are very highly conserved among mouse, human, and
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Fig. 2 MMP13 gene is an ETV4 target gene in mammary epithelial TAC and MMT cells. Effect of ETS/AP1 binding site mutations in the MMP13
promoter regulation. a Schematic representation of the mouse MMP13 promoter fragments (pMMP13–1800 to pMMP13–91) and AP-1 and/or
ETV4 mutant versions cloned into a pG3bLuc reporter vector (pG3b). Position of the conserved ETS binding sites (EBS) is represented by . AP-1
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rabbit [37, 38] (Additional file 4: Figure S2), and the EBS
was previously described to be important in MMP13 gene
promoter activity [38]. In fact, the mutation of the EBS
site in the MMP13 − 91 and MMP13 − 391 fragments re-
duced by half the transactivation by ETV4 (Fig. 2b). More-
over, AP-1 synergized the ETV4-induced transactivation
effect, and the AP-1 site is required for this activity
(Fig. 2c). We thereafter evidenced ETV4 recruitment to
this chromatin region in TAC and MMT cells by ChIP
using an antibody directed against ETV4, and, as a posi-
tive control, we analyzed the binding of ETV4 at the cyc-
lin D2 promoter, as previously described [8] (Fig. 2d). It is
noteworthy that the same results were obtained in TAC
and MMT cells that overexpress ETV4 (Additional file 5:
Figure S3). Therefore, MMP13 is an ETV4 target gene in
TAC and MMT mammary epithelial cells with AP-1 as a
likely coactivator.
ETV4 enhances cell proliferation, migration, invasion, and
anchorage-independent growth
Proliferation and migration assays showed that MMT cells
overexpressing ETV4 display enhanced proliferation and
migration abilities as determined using a Boyden chamber
(Fig. 3a and b). Similar results were obtained with or with-
out treatment with Mitomycin C, an inhibitor of prolifera-
tion, indicating that the effect on cell migration was not a
consequence of an increase in cell number (data not
shown). Moreover, invasion assay in a Matrigel®-overlaid
Boyden chamber and in a clonogenic assay revealed
that ETV4 significantly increases invasion (Fig. 3c)
and anchorage-independent growth (Fig. 3d) in vitro.
These data confirm that ETV4 is an important actor
of the cellular abilities (proliferation, migration, inva-
sion, anchorage-independent growth) involved in the
tumorigenic properties of MMT cells.
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Fig. 3 ETV4 enhances proliferation, migration, invasion, and anchorage-independent growth capacity of MMT mammary cancer cells. a MMT-Ctrl and
MMT-ETV4 cell proliferation analysis by cell counting. The two charts represent the number of counted cells at 10, 35, 55, 80, and 100 hours. Experiments
were conducted three times in triplicate. Error bars indicate SD. ***P≤ 0.001; **P≤ 0.01; *P≤ 0.1. b MMT-Ctrl and MMT-ETV4 cell migration analysis using
a Boyden chamber culture system. Histograms represent the relative number of counted cells that migrated to the lower side. The number of MMT-Ctrl
cells was arbitrarily = 1. Experiments were conducted three times in triplicate. Error bars indicate SD. ****P≤ 0.0001. The lower panel depicts a
representative picture of each experiment. Scale bar = 100 μm. c MMT-Ctrl and MMT-ETV4 cell invasion analysis using a Boyden chamber culture system
coated with Matrigel®. Histogram represents the relative number of cells that invaded to the lower side. The number of MMT-Ctrl cells was arbitrarily = 1.
Experiments were conducted three times in triplicate. Error bars indicate SD. ****P≤ 0.0001. The lower panel depicts a representative picture of each
experiment. Scale bar = 100 μm. d Anchorage-independent growth. MMT-Ctrl and MMT-ETV4 cells were cultured for 10 days in soft agar. This histogram
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bars indicate SD. ****P≤ 0.0001. The lower panel depicts a representative picture of each experiment. Scale bar = 100 μm
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MMP13 is a regulator of ETV4-dependent tumorigenic
properties in mammary cancer cells
Next, we evaluated the role of MMP13 during MMT cell
migration, invasion, or clonogenicity by using MMTcells in
which MMP13 is overexpressed (MMT-MMP13) or
knocked down by shRNA (MMT-shMMP13). MMP13
overexpression or repression was confirmed by qPCR
(Additional file 6: Figure S4a and b), Western blotting
(Additional file 6: Figure S4c) and/or zymography
(Additional file 6: Figure S4d). As shown in Fig. 4, MMP13
overexpression increases cell proliferation (Fig. 4a), migra-
tion (Fig. 4b), and anchorage-independent growth (Fig. 4c).
As expected, MMP13 repression leads to a reduction in
cell proliferation (Fig. 4d), cell migration (Fig. 4e), and
anchorage-independent cell growth (Fig. 4f ). Thus,
similarly to ETV4, but with a weaker effect, MMP13 is an
inducer of cancer cell proliferation, migration, and invasion.
In order to determine if MMP13 participates in
ETV4-regulated cancer cell properties, we repressed
MMP13 in the ETV4-overexpressing MMT cell line.
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To that end, we established the MMT-ETV4 + shMMP13
cell line, which expresses an MMP13-shRNA construct
allowing for a significant reduction in MMP13 mRNA
expression and subsequently a reduction in MMP13
metalloprotease activity (Fig. 5a and b). Importantly, as
determined by qPCR and Western blotting, ETV4 mRNA
and protein expression remains unchanged in these cells
(Additional file 7: Figure S5a and b). The repression of
MMP13 in the ETV4-overexpressing MMT cells drastic-
ally decreases their proliferation (by 60% at 100 hours
after the beginning of the experiment) (Fig. 5c) and signifi-
cantly reduces cell migration (twofold decrease compared
with ETV4 + shCtrl) (Fig. 5d), cell invasion (twofold
decrease compared with ETV4 + shCtrl) (Fig. 5e), and
anchorage-independent growth (2.5-fold increase com-
pared with ETV4 + shCtrl) (Fig. 5f). This was confirmed
by transient transfection of a siRNA directed against
MMP13 in the MMT-ETV4-overexpressing cells,
which led to a 60% decrease in MMP13 expression
(Additional file 8: Figure S6a) and a significant reduc-
tion in anchorage-independent cell growth (Additional
file 8: Figure S6b). Altogether, these results show that
MMP13 acts as a relay of ETV4 to control mammary
cancer cells’ tumorigenic abilities.
MMP13 silencing inhibits the tumorigenic activity of ETV4
in vivo
To investigate whether MMP13 expression is necessary
for the induction of tumors by ETV4 in vivo,
MMT-ETV4 + shCtrl and MMT-ETV4 + shMMP13 cells
were injected into the inguinal flanks of immunocom-
promised mice, and tumor growth was evaluated every 3–
4 days (Fig. 6). Three days postinjection, all of the mice
that received an injection of MMT-ETV4 + shCtrl cells
showed a palpable tumor, whereas none could be detected
at this stage in the group that received an injection of
MMT-ETV4 + shMMP13 cells. By day 6 postinjection, all
MMT-injected mice developed palpable tumors. However,
a 3–4-day measurement of tumor size over the course of
10 more days (until animals were killed) indicated that
MMP13 expression was required for optimal tumor
growth because MMP13-shRNA-expressing ETV4 cells
are, on average, twofold smaller than controls. Immuno-
cytochemistry performed on paraffin-embedded mouse
tumor tissue sections showed an equivalent Ki-67 expres-
sion in tumors from ETV4 + shCtrl and ETV4 +
shMMP13 cells, which all show proliferative activity.
Cleaved caspase 3 expression showed that apoptosis
events are present in both conditions, to a slightly greater
extent in the ETV4 + shMMP13 tumors, according to
their slow growth. ETV4 expression is, as expected,
equivalent in both ETV4-expressing cell-derived tumors.
In contrast, MMP13 expression decreased in ETV4 +
shMMP13-derived tumors, thus confirming the suitable
MMP13 regulation (here a repression) in these in vivo as-
says (Fig. 6b). Therefore, these data bring out that
MMP13 is a mediator of ETV4 tumorigenic activity in
MMTcancer cells.
MMP13 and ETV4 expression in breast tumors is
associated with a poor prognosis
In order to corroborate the relevance of the phenotypic
and mouse in vivo data and to explore the link between
ETV4 and MMP13 in human breast cancer, we assessed
MMP13 and ETV4 mRNA expression levels in a series
of 456 primary unilateral invasive primary breast tumors
from patients with known clinical and pathological sta-
tus and long-term outcome. We used a log-rank test to
identify relationships between MFS and MMP13 and/or
ETV4 expression. Tumors with the highest levels of
MMP13 mRNA (n = 135 [29.6%]) were significantly as-
sociated with poor MFS (P = 0.00016), which was not
the case for ETV4-expressing tumors (Additional file 9:
Figure S7a and b). This result was confirmed in the NKI
breast cancer cohort (Additional file 10: Figure S8b and
c). Combined analysis (as described in the “Patients and
samples for MMP13 and ETV4 expression” subsection
of the Methods section above) of MMP13 and ETV4
mRNA expression levels defined three separate prognos-
tic groups of 82 (Low-ETV4), 255 (High-ETV4/
Low-MMP13), and 119 (High-ETV4/High-MMP13) pa-
tients with significantly different survival (P = 0.000041)
(Fig. 7). The patients with the poorest prognosis were
observed in the subgroup of 119 of 456 (26.1%) patients
characterized by association of high MMP13 and high
ETV4 mRNA expression levels. These data were also
confirmed in the NKI breast cancer cohort (P = 0.0013)
(Additional file 10: Figure S8a). Multivariate analysis
using a Cox proportional hazards model was performed
to assess the prognostic value for MFS of the parameters
found to be significant in univariate analysis (i.e., SBR
histological grade, lymph node status, macroscopic
tumor size, PR status [Additional file 2: Table S1]
and combined MMP13 and ETV4 mRNA levels).
The prognostic significance of the lymph node status
(P = 0.000016), macroscopic tumor size (P = 0.0028),
and combined MMP13 and ETV4 mRNA level was
maintained (Additional file 11: Table S2).
We sought links between the three prognostic groups
and classical clinicopathological parameters in breast
cancer (Table 1). Using HR (ERα and PR) and ERBB2
status, we also subdivided the total population (n = 456)
into four breast cancer molecular subtypes: HR+/ERBB2+
(n = 54), HR+/ERBB2− (n = 289), HR−/ERBB2+ (n = 45)
and HR−/ERBB2− (n = 68). High MMP13 and ETV4
mRNA expression levels were associated with negative
ER status (P = 0.00067) and the HR−/ERBB2+ subtype
(P = 0.0015), two parameters associated with breast
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Fig. 5 MMP13 acts as a regulator of ETV4 tumorigenic-induced response in mammary epithelial MMT cells. a Relative MMP13 mRNA expression in
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by cell counting. The two charts represent the number of counted cells at 10, 35, 55, 80, and 100 hours. Experiments were conducted three times
in triplicate. Error bars indicate SD. ****P ≤ 0.0001; ***P≤ 0.001; **P≤ 0.01. d MMT-ETV4 + shCtrl and MMT-ETV4 + shMMP13 cell migration analysis
using a Boyden chamber culture system. Histogram represents the relative number of counted cells that migrated to the lower side. The number
of MMT-ETV4 + shCtrl cells was arbitrarily = 1. Experiments were conducted three times in triplicate. Error bars indicate SD. ****P≤ 0.0001. The
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invasion analysis using a Boyden chamber culture system coated with Matrigel®. Histograms represent the relative number of counted cells that
invaded to the lower side. The number of MMT-ETV4 + shCtrl cells was arbitrarily = 1. Experiments were conducted three times in triplicate. Error
bars indicate SD. ****P ≤ 0.0001. The lower panel depicts a representative picture of each experiment. Scale bar = 100 μm. f Anchorage-
independent growth. MMT-ETV4 + shCtrl and MMT-ETV4 + shMMP13 cells were cultured for 10 days in soft agar. This histogram represents the
number of clones counted for experimental time points. Soft agar assays were conducted three times in triplicate. Magnification × 5. Error bars
indicate SD. ****P ≤ 0.0001. The lower panel depicts a representative picture of each experiment. Scale bar = 100 μm
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cancer aggressiveness (Table 1). We did not observe a
correlation between the three prognostic groups and
mutations of PIK3CA, which is the most frequently
mutated oncogene in breast cancer (P = 0.96), as well
as mRNA level of the MKI67 gene, which encodes for
the proliferation-related Ki-67 antigen (P = 0.073).
Discussion
ETV4 is an ETS transcription factor involved in import-
ant steps of organ development, such as in mammary
gland morphogenesis. ETV4 is also a significant medi-
ator of tumorigenesis through the activation of several
downstream pathways that are associated with migration
and invasion. ETV4 is overexpressed in breast tumors
and is associated with distant metastasis and poor prog-
nosis [1, 5, 39, 40]. However, the cellular and molecular
events regulated by this factor remain poorly under-
stood. We previously identified target genes implicated
in phenotypic cellular modulation induced in mammary
tumorigenesis as Bax or cyclin D2. We have described cyc-
lin D2 to act as a negative regulator of the ETV4-induced
responses in mammary cancer cells [8, 12]. We also de-
scribed that ETV4 overexpression in a mammary epithelial
cell line confers tumorigenesis-like properties as well as an
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increased ability to grow [32] and that ETV4 repression re-
duces tumorigenesis in mammary cancer cells [16].
In this work, we demonstrate that ETV4 enhances
tumorigenic properties of mammary epithelial cancer
cells (MMT cells) and that MMP13, as an ETV4 target
gene, relays these effects. ETV4 is now well known to be
involved in events participating in tumor development
and progression. For example, repression of ETV4 in
colorectal carcinoma cells significantly impairs their in-
vasive capacity [41], and several EMT markers and
MMPs were downregulated in shETV4-expressing cells.
In the same way, in gastric adenocarcinoma cell lines,
ETV4 increases MMP1 and MMP7 expression and stim-
ulates invasion in vitro [42]. Ectopic overexpression of
ETV4 in nonmetastatic human breast cancer cells in-
creases their invasiveness and their metastatic potential
in nude mice [43]. Therefore, deregulated metallopro-
tease expression and/or activity have often been associ-
ated with ETV4 tumorigenic properties [1, 44]. However,
the precise molecular mechanism by which they act dur-
ing mammary tumorigenesis is currently unknown.
MMT cells, a mammary tumorigenic cell model, have
previously been used to explore the functional involve-
ment of ETV4 in their tumorigenic properties [16].
ETV4 downregulation in MMT cells leads to a decrease
in their tumor-forming abilities. Similarly, we show that
ETV4 overexpression in MMT cells promotes cell prolif-
eration, migration, invasion, and anchorage-independent
growth, demonstrating that ETV4 is an actor of tumori-
genic development, as previously described.
Among the well-known MMPs associated with tumori-
genic occurrences, MMP13 is a metalloprotease playing an
important role in tissue remodeling during fetal and subse-
quent postnatal bone development [45, 46]. Nevertheless,
MMP13 was first identified in a breast tumor library [17],
and an increasing amount of data demonstrates its role in
tumorigenesis and particularly in breast cancer [22, 24, 27,
47]. In accordance with this, on the basis of transcriptomic
analysis, we initially described regulation of MMP13 ex-
pression by ETV4 in a mammary epithelial cell line [16].
To shed light on the functional relevance of the
ETV4-MMP13 interplay, we explored MMP13 expres-
sion in different contexts of murine (TAC, MMT) or
human (MCF10A) ETV4-expressing cells and analyzed
the regulation of the MMP13 gene by ETV4. MMP13
expression and activity are positively correlated with
ETV4 expression. Moreover, ETV4 is a transactivator of
the MMP13 gene promoter because we identified a
91-bp minimal promoter that contains putative ETS and
AP-1 binding sites. We detected the binding of ETV4 to
this chromatin region, the cooperation between ETV4
and AP-1 to enhance the transactivation effect of ETV4
and the importance of the proximal EBS, and the re-
quirement of the AP-1 binding motif, a known cofactor
of various ETS proteins [43, 48–51]. This synergistic ac-
tion between AP-1 and ETV4 in MMP13 regulation could
emphasize the role of MMP13 in the ETV4-dependent
tumorigenic effects and serve as a potential target to treat
ETV4-driven diseases.
Given that MMPs are key actors of the tumorigenic and
metastatic processes, we evaluated the influence of
MMP13 on phenotypic modification of mammary cancer
cells and in a context of ETV4 overexpression. On the one
hand, MMP13 overexpression is able to slightly increase
cell proliferation, migration, and anchorage-independent
growth, and on the other hand, MMP13 repression has
the reverse effect. In fact, MMP13 has the same behavior
as ETV4 in these cancer cells but is less potent. These are
relevant findings, considering that MMP13 is overex-
pressed in a variety of malignant tumors, such as in breast
carcinomas [20, 52, 53], and is implicated in bone metas-
tasis in breast cancer [23, 54, 55].
In order to determine if MMP13 is a relay of ETV4
tumorigenic activity, we compared the behavior of
MMT cells overexpressing ETV4 and at the same time
have a downregulation of MMP13 expression and activ-
ity. These ETV4-overexpressing/MMP13-silencing cells
show a significant decrease of their proliferation, migra-
tion, and anchorage-independent growth rate. Further-
more, we provide evidence that the silencing of MMP13
inhibits ETV4-induced tumor formation in mice, con-
firming the in vitro data and highlighting the importance
of MMP13 activity in ETV4 tumorigenic functions.
Even though numerous studies suggested the import-
ance of MMP13 in tumor progression and metastasis de-
velopment, by describing its up- or downregulation, very
few of them analyzed the impact of these modulations.
One of them, by using a similar approach to studying
the role of Pit1, a POU class 1 homeobox 1 transcription
factor, revealed that it regulates MMP13 expression in
100
25
75
50
M
et
as
ta
si
s-
fr
ee
 s
u
rv
iv
al
 (%
)
Time (months)
300100 200 4000
0
p=0.000041
High MMP13 and High ETV4 (n=119)
Low ETV4 (n=82)
Low MMP13 and High ETV4 (n=255)
Fig. 7 MMP13 and ETV4 are associated with poor prognosis in
breast cancer. Metastasis-free survival (MFS) curves for patients with
breast tumors according to Low-ETV4 (n = 82), High-ETV4 and Low-
MMP13 (n = 255), or High-ETV4 and High-MMP13 (n = 119) mRNA
levels. ****P ≤ 0.0001
Dumortier et al. Breast Cancer Research  (2018) 20:73 Page 13 of 18
Table 1 Relationship between MMP13 and ETV4 transcripts levels and classical clinical biological parameters in 456 breast cancer
samples
Number of patients (%)
Total population (%) Low ETV4 High ETV4-Low MMP13 High ETV4-High MMP13 P valuea
Total 456 (100.0) 82 (18.0) 255 (55.9) 119 (26.1)
Age, yr
≤ 50 98 (21.5) 10 (12.2) 60 (23.5) 28 (23.5) 0.075 (NS)
> 50 358 (78.5) 72 (87.8) 195 (76.5) 91 (76.5)
SBR histological gradeb, c
I 58 (13.0) 10 (12.3) 37 (15.0) 11 (9.2) 0.24 (NS)
II 229 (51.2) 48 (59.3) 122 (49.4) 59 (49.6)
III 160 (35.8) 23 (28.4) 88 (35.6) 49 (41.2)
Lymph node statusd
0 119 (26.1) 21 (25.9) 67 (26.5) 31 (26.3) 0.085 (NS)
1–3 237 (52.1) 37 (45.7) 144 (56.9) 56 (47.5)
> 3 96 (21.8) 23 (28.4) 42 (16.6) 31 (26.3)
Macroscopic tumor sizee
≤ 25 mm 223 (49.8) 40 (50.0) 132 (52.4) 51 (44.0) 0.32 (NS)
> 25 mm 225 (50.2) 40 (50.0) 120 (47.6) 65 (56.0)
ERα status
Negative 118 (25.9) 9 (11.0) 67 (26.3) 42 (35.3) 0.00067
Positive 338 (74.1) 73 (89.0) 188 (73.7) 77 (64.7)
PR status
Negative 194 (42.5) 31 (37.8) 103 (40.4) 60 (50.4) 0.12 (NS)
Positive 262 (57.5) 51 (62.2) 152 (59.6) 59 (49.6)
ERBB2 status
Negative 357 (78.3) 71 (86.6) 200 (78.4) 86 (72.3) 0.052 (NS)
Positive 99 (21.7) 11 (13.4) 55 (21.6) 33 (27.7)
Molecular subtypes
HR−ERBB2− 68 (14.9) 8 (9.8) 41 (16.1) 19 (16.0) 0.0015
HR−ERBB2+ 45 (9.9) 1 (1.2) 22 (8.6) 22 (18.5)
HR+ERBB2− 289 (63.4) 63 (76.8) 159 (62.4) 67 (56.3)
HR+ERBB2+ 54 (11.8) 10 (12.2) 33 (12.9) 11 (9.2)
PIK3CA mutation status
Wild type 307 (67.3) 56 (68.3) 172 (67.5) 79 (66.4) 0.96 (NS)
Mutated 149 (32.7) 26 (31.7) 83 (32.5) 40 (33.6)
MKI67 mRNA expression
Median 12.5 (0.80–117) 11.7 (1.74–117) 12.1 (0.80–94.5) 13.6 (2.1–58.5) 0.073 (NS)
Abbreviations: ERα Estrogen receptor alpha, PR Progesterone receptor, ERBB2 Human epidermal growth factor receptor 2, HR Hormone receptor, PIK3CA
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha, MKI67 Marker of proliferation Ki-67
The bold values are statistically significant (P < 0.05)
Numbers represent the part of the 456 patients in each condition (e.g., age, SBR histological grade) and in regard to the expression level group (Low ETV4/High
ETV4-Low MMP13/High ETV4-High MMP13). For these three groups, percentages in brackets correspond to the proportion of patients in the group (82 for Low
ETV4; 255 for High ETV4-Low MMP13; 119 for High ETV4-High MMP13)
a χ2 test
bScarff Bloom Richardson classification
cInformation available for 447 patients
dInformation available for 452 patients
eInformation available for 448 patients
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human breast cancer cells and that MMP13 knock-down
blocks cancer cell invasion into the lungs, suggesting
that MMP13 is a mediator of Pit1 induction of breast
cancer lung metastasis [56]. These data underline the
importance of MMP13 in the mediation of tumorigen-
esis and invasiveness and corroborate our findings.
The MMT cell model was considered to be a useful
model in which to perform the in vitro and in vivo
phenotypic assays according to the previously published
data and characterization we obtained regarding their
ability to form tumors in immunodeficient mice [8, 16].
Indeed, to decipher the relevance of ETV4 and MMP13
association in breast cancer, we assessed MMP13 and
ETV4 mRNA expression levels in a series of 456 breast
cancer samples. Even if high ETV4 mRNA expression
was not shown to be associated with poor MFS, the
group with a high MMP13 mRNA expression level was
significantly associated with a bad prognosis (P =
0.00016). Nevertheless, by combining MMP13 and ETV4
mRNA expression status, we identified three distinct
prognostic groups with significantly different MFS
curves (P = 0.000041). These data revealed that the
tumor group overexpressing both ETV4 and MMP13 is
correlated with the poorest prognosis, much more sig-
nificant than that of MMP13 alone. These results were
confirmed in the NKI breast cancer cohort (P = 0.0013),
reinforcing the high prognostic value of ETV4- and
MMP13-associated high expression. Moreover, this cor-
relation was strengthened by the independent prognostic
value shown for combined high expression levels of
ETV4 and MMP13 (P = 0.000041). Indeed, our study
suggests an important interplay of ETV4 and MMP13 in
human breast cancers that could, together, be assessed
for their possible signature for guiding diagnosis or
therapeutics.
ETV4 overexpression is associated with increased meta-
static risk and poor patient survival in triple-negative
breast cancer distant metastasis and poor patient survival
[57]. Similarly, high levels of MMP13 expression are asso-
ciated with high tumor aggressiveness and poor survival
rate [58]. Thus, these data corroborate our findings, and
in combination, they underline the importance of these
two factors, ETV4 and its relay MMP13, in mammary
tumorigenesis. Nevertheless, the real way by which they
interplay needs to be deciphered, and further investiga-
tions should be done to evaluate their potential as prog-
nostic and diagnostic markers as well as potential
therapeutic targets to prevent or treat the disease.
Conclusions
The ETV4 transcription factor is involved in tumorigenesis
and metastatic processes, particularly in breast cancer, a
heterogeneous illness with different subtypes. In the present
study, we showed that ETV4 promotes proliferation,
migration, invasion, and anchorage-independent growth of
mammary tumorigenic MMT cells. In parallel, we identified
MMP13, an extracellular metalloprotease, as an ETV4 target
gene. We showed that, by overexpressing or repressing
MMP13 expression, this metalloprotease contributes to
ETV4-induced proliferation, migration, and clonogenicity
capacity. Thus, MMP13 acts as a relay of ETV4 in its
functional role in the mammary epithelial tumorigenic
cells in vitro as well as in tumor development in animal
models. Finally, we showed that ETV4 and MMP13
co-overexpression is correlated with poor prognosis in
breast cancer. Taken together, these data highlight the
role of these actors in mammary tumorigenesis and
breast cancer progression and underline the potential
prognostic value of their combined expression in breast
cancer.
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